Assistant Professor of Medicine
NYU Hospital for Joint Diseases
Division of Rheumatology
New York, United States
Dr. Wampler Muskardin is an Assistant Professor of Medicine, physician-scientist in Rheumatology and member of the Colton Center for Autoimmunity at NYU Langone Medical Center, NY, NY, USA. She completed training in both adult and pediatric Rheumatology at the University of Minnesota, where she began research in Type I interferon and TLR pathways. While a junior faculty member at Mayo Clinic, she began training in the laboratory of Timothy Niewold. MD. Dr. Wampler Muskardin and Dr. Niewold recently moved to NYU, where Dr. Niewold is the Judith and Stewart Colton Professor of Medicine and Pathology, Director of the Colton Center for Autoimmunity. Dr. Wampler Muskardin’s current research focuses on human studies of type I IFN and TLR pathways in understanding response to treatment in inflammatory arthritis.
Judith and Stewart Colton Professor of Medicine and Pathology
Director, Colton Center for Autoimmunity
NYU School of Medicine
New York, NY 10016
Dr. Timothy Niewold is the Judith and Stewart Colton Professor of Medicine and Pathology at New York University School of Medicine. He is a physician-scientist, and directs the Colton Center for Autoimmunity, which focuses on the identification of causal factors and new treatment targets in autoimmune disease. Working as a human geneticist and translational researcher, Dr. Niewold bridges the traditional gap between the basic and clinical sciences. Work is his laboratory focuses on identifying and understanding the pathogenic factors in human autoimmune disease, and the ways in which underlying genetic risk factors impact immune responses to result in disease. His laboratory is supported by a number of federal, foundation, and industry grants. Dr. Niewold is recognized for important contributions to our understanding of how genes influence pathogenic cytokine patterns that give rise to human lupus. He has published more than 140 papers in the fields of Immunology, Genetics, and Rheumatology, and is a member of numerous editorial boards and advisory committees, including serving as an Associate Editor for the Cytokine journal. He is the Chair of the Scientific Advisory Council of the American College of Rheumatology Research Foundation, the President-Elect of the Central Society for Clinical and Translational Research, and a standing NIH study section member.
Brigham and Women’s Hospital / Harvard Medical School
Boston, United States
Dr. Niro Anandasabapathy is Assistant Professor of Dermatology at Harvard Medical School and physician-scientist in Dermatology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Dr. Anandasabapathy performed her undergraduate studies in Biology and Art History at Stanford University. She received her PhD in Cancer Biology and her MD from Stanford. She became a Fellow of the American Academy of Dermatology in 2009 and received a Masters of Science in Clinical and Translational Science from Rockefeller University. Dr. Anandasabapathy started her own lab at BWH in 2013. At the Anandasabapathy Lab, scientists pursue translational research in the areas of cancer immunotherapy, vaccine development, dendritic cell biology, drug development (eg. Flt3L), drug discovery, and immune priming. She and her colleagues also delve into the immune response to diseases such as basal cell carcinoma, melanoma, vaccinia virus, and HIV.
Department of Immunology
Yokohama City University Graduate School of Medicine
Yokohama City, Japan
Dr. Ban received his Ph.D. in 2012 from the University of Tokyo, Japan under the mentorship of Prof. Tadatsugu Taniguchi. During his Ph.D. course, he studied the innate immune sensing mechanisms of nucleic acids derived from viruses or other pathogens, and contributed to publishing two Nature papers and three Proc Natl Acad Sci USA papers. After receiving his Ph.D., Dr. Ban joined the laboratory of Prof. Tomohiko Tamura at the Department of Immunology, Yokohama City University Graduate School of Medicine, and has been studying the activation mechanism of the IRF transcription factor family, and developing novel therapeutics for autoimmune diseases. He showed in a mouse model of systemic lupus erythematosus (SLE) that hyperactivation of IRF5 causes the development of an SLE-like disease, and that the selective suppression of IRF5 is key to the new therapeutics for SLE. His work was published in Immunity in 2016. He recently works on a project for the development of the IRF5 inhibitor as an innovative drug for SLE.
The George Washington University, The GW Cancer Center
800 22nd St NW
Washington, DC, United States
Dr. Katherine Chiappinelli joined the GW Department of Microbiology, Immunology and Tropical Medicine University in 2017 as an Assistant Professor in January 2017. She graduated with a B.S. in Biology and Music from Haverford College in 2007 and received her Ph.D. in Developmental, Regenerative, and Stem Cell Biology from Washington University in St. Louis under the supervision of Dr. Paul Goodfellow in 2012. Dr. Chiappinelli pursued postdoctoral studies at Johns Hopkins University with Dr. Stephen Baylin investigating the epigenetic control of immune signaling in cancer cells. Her research focuses on how epigenetic therapies can be used against cancers, specifically in the context of arming the host immune system to fight cancer cells. Kate is passionate about undergraduate science education and community science outreach, with extensive experience working with high school students in urban environments.
Department of Chemistry and Institute for Advanced Study
Technical University of Munich
Dr. Feige is an Assistant Professor at the Department of Chemistry and Institute for Advanced study at the Technical University of Munich (TUM). He completed his doctoral training in Prof. Johannes Buchner’s lab at the TUM where he studied mechanisms of antibody folding and assembly using biophysical approaches. As a postdoctoral fellow in Linda Hendershot’s lab at the St. Jude Children’s Research Hospital, Matthias applied biochemical and cell biological techniques to study the biogenesis and quality control of T cell receptor assembly as well as principles of chaperone function in the ER. Using an interdisciplinary approach from in vitro protein biochemistry and biophysics to immune cell biology, his lab now investigates how interleukins fold and assemble in the cell. Insights into these processes have immediate implications for the regulation of immune signaling – but also the design of optimized and novel immune modulators.
Professor, President & Director
Biomedical Sciences Research Center “Alexander Fleming”
George Kollias is Member of the Academy of Athens, Professor of Experimental Physiology at the Medical School of the University of Athens, and President and Director at the Biomedical Sciences Research Center “Alexander Fleming” (2002-2010 & 2016-present). He completed his Ph.D. in Molecular Biology at the National and Kapodistrian University of Athens, Greece and his postdoctoral training at the National Institute for Medical Research, Laboratory of Gene Structure and Expression, Mill Hill, London, UK. Prof. Kollias has pioneered genetic approaches to study the function of cytokine signaling in animal models of human diseases, with specific focus on Tumor Necrosis Factor (TNF). His lab is renowned for proof of principle preclinical studies that led to the development of anti-TNF therapies for rheumatoid arthritis and for advancing knowledge on molecular and cellular mechanisms driving chronic inflammation and autoimmunity (e.g. Rheumatoid Arthritis, Inflammatory Bowel Disease and Multiple Sclerosis). Prof. Kollias’ efforts developed almost exclusively in Greece, and his scientific and administrative work has contributed decisively to the support of a new generation of Greek scientists and the development National Infrastructures of scientific and technological excellence. In 2006 he founded the first CRO-biotech spin-off of BSRC Fleming, Biomedcode Hellas SA. In 2014, he was awarded the Carol-Nachman Award for Rheumatology and in 2015 he received the first Galien Scientific Research Award at the Prix Galien Greece. Prof. Kollias is Director of the Graduate Program in “Molecular Biomedicine” at the Medical School of the University of Athens.
Associate Professor of Immunology – Allergology
Department of Immunology
Faculty of Medicine
Felix Houphouet-Boigny University
Abidjan, Cote d’Ivoire
Dr Siransy is Associate Professor in Immunology and Allergology at Felix Houphouet–Boigny University, Faculty of Medicine since 2015, and she is the national Head of Laboratory at National Blood Transfusion Center in Abidjan, Cote d’Ivoire. Recently, she completed her training in Allergology at the University Claude Bernard of Lyon, France. For decades, she has been heavily professionally involved in the field of transfusion in Cote d’Ivoire and in Africa as well. She is trainer of trainers with African Blood Transfusion society.
Currently, she is working on her PhD Dissertation on Sickle Cell Disease (SCD). Her work desires to bring a contribution to the clarification of the in vivo biological functions of cytokines as well as to demonstrate how these biomarkers may be helpful for phenotyping SCD patients for both research and therapy.
Assistant Professor, Tenure-Track
Department of Medicine
Center for Inflammation, Infectious Diseases, and Immunity
Quillen College of Medicine
East Tennessee State University
Dr. Shunbin Ning is an assistant professor in the Department of Internal Medicine, East Tennessee State University, USA. He is interested in the interaction between tumor viruses and the host innate immune system in the development of AIDS-related malignances. His research focuses on the molecular mechanisms and signaling pathways underlying the crosstalk between innate immune response and viral oncogenesis. The long-term goal of these studies is to identify molecular targets for immunotherapeutic and antiviral therapeutic applications for AIDS-related viral malignancies.
National Brain Research Centre
Dr. Ellora Sen did her PhD in Immunology from the Indian Institute of Chemical Biology, where she studied the interface of Leishmania with macrophages. As a post-doctoral fellow at the Department of Microbiology & Immunology, Pennsylvania State University she investigated mechanism affecting transcriptional regulation of viral oncogenes. She then moved on as Research Associate in the Department of Neurology and Neurosciences, Rutgers University. Here, she studied the importance of cytokine signaling in determining specification of glial precursors within the sub-ventricular zone. Since 2006 she has been a staff scientist at the National Brain Research Centre, India. As an independent investigator, she consolidated her training in immunology, gene regulation and neuroscience towards understanding the role of inflammation in brain cancer. The overall focus of her laboratory is to unravel how inflammation regulates transcriptional network and chromatin dynamics to affect genes associated with immune evasive responses and metabolic adaptation in glioblastoma.
Senior Research Fellow
Dr. Megan Stanifer is a senior research fellow in the laboratory of Dr. Steeve Boulant at Heidelberg University. She completed her PhD from Brown University in the laboratory of Dr. Walter Atwood where her work focused on understanding the host-pathogen interactions of the human polyomaviruses JC and BK. Her first post-doctoral training was completed at Harvard Medical School in the laboratory of Dr. Sean Whelan. In the Whelan lab, Dr. Stanifer developed advanced microscopy methods to visualize and manipulate the site of fusion of vesicular stomatitis virus (VSV) to understand how impacting virus delivery would affect the cellular immune response. Her second post-doctoral training in the lab of Dr. Boulant has focused on understanding how the polarized cells of the human intestinal tract control their intrinsic innate immune response to enteric pathogens. Dr. Stanifer’s work has revealed a key role of the polarized sorting machinery and type III IFNs in the protection of the gut epithelium.
QIMR Berghofer Medical Research Institute
Herston, Queensland, Australia
Dr Michele Teng is head of the Cancer Immunoregulation and Immunotherapy Laboratory at the QIMR Berghofer Medical Research Institute in Brisbane, Australia. She completed her PhD in 2006 at the Peter MacCallum Cancer Centre and University of Melbourne, Australia. Her group is investigating how tumour-induced immune suppression impedes the effective treatment of established cancer. Specifically, she is interested in examining the role of T regulatory cells (Tregs), T-cell anergy/exhaustion, and the IL-23-associated cytokine family in the local tumour microenvironment using experimental and de novo models of cancer. In addition, her group is determining how scheduling of immunotherapies in a neoadjuvant setting can further improve their antitumour efficacy. Her group have also developed a preclinical mouse model to assess how different combination therapies impact on tumour immunity and immune related adverse events.